Sylvester Comprehensive Cancer Center

E-mail a Friend

Marc E. Lippman, M.D.

General Information

Marc E. Lippman, M.D.

Languages

  • English

Certifications

  • American Board of Internal Med-Medical Oncology
  • American Board of Internal Medicine
  • American Bd of Int Med-Endocrinology Diabetes & Metabolism

Specialties

  • Hematology/Oncology - Internal Medicine
  • Internal Medicine

Roles

  • Deputy Director, Sylvester Comprehensive Cancer Center
  • Kathleen & Stanley Glaser Professor

Education

1976-1988 Head, Medical Breast Cancer Section,
Medicine Branch, NCI, NIH
1974-1988 Senior Investigator
Medicine Branch, NCI, NIH
1973-1974 Fellow in Endocrinology
Yale Medical School, New Haven, CT
1970-1988 Officer USPHS
Osler Medical Service, Johns Hopkins Hospital
1970-1971 Clinical Associate
Leukemia Service, NCI, National Institutes of Health
1970-1971 Clinical Assicociate
Laboratory of Biochemistry, NCI, NIH
1969-1970 Assistant Resident
Osler Medical Service, Johns Hopkins Hospital
1968-1970 Intern
Osler Medical Service, Johns Hopkins Hospital

Publications

  • Goka E, Lippman ML. Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression. Oncogene. In press.
  • Smidt ML, Moossdorff M, van Roozandaal LM, Strobbe LJA, Members of the Maastricht Breast Cancer Endpoints Consensus Group. Maastricht Consensus on definitions of local event, second primary breast cancer, regional event, and distant event in breast cancer research: Results of an international Delphi study. JNCI. 106(12), 2014
  • Drews-Elger K, Iorns E, Dias A, Ward TM, Dean S, Clarke, Miller P, Campion-Flora A, Nava Rodrigues D, Reis-Filho JS, Rae JM, Thomas D, Berry D, El-Ashry D and Lippman ME. Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome. Breast Cancer Research and Treatment. 148 (1): 41-59, 2014
  • Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ML, El-AShry D. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cacner-associated fibroblasts in dissociated tumor (DT) cultures. Breast Cancer Research and Treatment. 2014 Feb; 144: 503-517
  • Dan T, Hewitt SM, Ohri N, Ly D, Soule BO, Smith SL, Matsuda K, Council C, Shankavaram U, Lippman ME, Mithcell JB, Camphausen K, Simone NL. CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up. Breast Cancer Research and Treatment. 2014 Jan; 143(1): 11-8. Epub 2013 Nov 26
  • Sandoval-Leon, A., Drews-Elger, K., Gomez-Fernandez, C., Yepes, M.M., Lippman, M.E. Paget’s disease of the nipple. Breast Cancer Research and Treatment. 2013 Aug; 141(1):1-12
  • Iorns E, Drews-Elger K, Ward TM, Dean S, Clarke J, Berry D, El Ashry D, Lippman M. A new mouse model for the study of human breast cancer metastasis. PLoS One. 2012;7(10):e47995. Epub 2012 Oct 31
  • Sikora, M. J., Strumba, V., Lippman, M.E., Johnson, M.D., and Rae, J. Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. Breast Cancer Research and Treatment. 2012 Aug; 134(3):1027-39. Epub 2012 Mar 29
  • Ward TM, Iorns E, Liu X, Hoe N, Kim P, Singh S, Dean S, Jegg AM, Gallas M, Rodriguez C, Lippman ME, Landgraf R, Prgram MD. Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic Xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene. 2012 March; 32:2463-2474. Epub 2012 July 2
  • Wong JS, Iorns E, Rheault MN, Ward TM, Rashmi P, Weber U, Lippman ME, Faul C, Mlodzik M, Mundel P. Rescue of tropomyosin deficiency in Drosophila and human cancer cells by synatopodin reveals a role of tropomyosin a in RhoA stabilization. EMBO Journal. 2011 Dec 13; 31 (4): 1028-40
  • Simone, C. B., Dan, T. D., Shih, J., Smith, S., Sciuto, L., Lita, E., Lippman, M.E., Glatstein, E., Swain, S. M., Danforth, D., and Camphausen, K. Twenty-Five year results of the national Cancer Institute Randomized Breast Conservation Trial. Breast Cancer Res Treat. 2012 Feb;132 (1):197-203. Epub 2011 Nov 24
  • Iorns, E., Clarke, J., Ward, T.M., Dean, S. and Lippman, M. Simultaneous analysis of tumor and stromal gene expression profiles from xenograft models. Breast Cancer Res Treat. 2012 Jan;131(1):321-4. Epub 2011 Sep 24
  • Ward TM , Iorns E , Liu X , Hoe N , Kim P , Singh S , Dean S , Jegg AM , Gallas M , Rodriguez C , Lippman M , Landgraf R , Pegram MD .. Truncated p110 ERBB2 indeces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene, 2013 May 9;32(19):2463-74. Epub 2012 Jul 2
  • Iorns, E., Ward, T. M., Dean, S., Jegg, A., Lord, C. J., Murugaesu, N., Sims, D., Mitsopoulos, C., Fenwick, K., Kozarewa, I., Naceur-Lombarelli, C., Zvelebil, M., Isacke, C., Ashworth, A., Hnatyszyn, J., Pegram, M. and Lippman, M. Whole genome in vivo RNAi screening identifies the Leukemia Inhibitory Factor Receptor as a novel breast tumor suppressor. Breast Cancer Res Treat. 2012 Aug;135(1):79-91. Epub 2012 Apr 26
  • Iorns, E., Hnatyszyn, H.J., Seo, P., Clarke, J., Ward, T. and Lippman, M.E. The Role of SATB1 in Breast Cancer Pathogenesis. Journal of the National Cancer Institute. 2010 August; 102(16): 1284-96.
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast. J Natl Cancer Inst Monogr. 2010; (41): 162-177

Biography

Marc E. Lippman, M.D. was named the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard M. Miller School of Medicine, and was named Chairman of the Department of Medicine in May 2007. Previously Dr. Lippman was the John G. Searle Professor and Chair of Internal Medicine at the University of Michigan, Ann Arbor, Michigan. From 1988 through 1999 Dr. Lippman was Professor of Medicine and Pharmacology, and Chair, Department of Oncology at Georgetown University in Washington, D.C., and served as Director of the Lombardi Cancer Center at Georgetown University Medical Center. From 1978 through 1990 he was Clinical Professor of Medicine and Pharmacology, Uniformed Services, University of the Health Sciences. Dr. Lippman served as Head of the Medical Breast Cancer Section, Medicine Branch, at the National Institute of Health. He was a Senior Investigator at the National Cancer Institute of the National Institute of Health. Dr. Lippman completed a Fellowship in Endocrinology at Yale Medical School in New Haven, CT from 1973-1974. In addition, he was Clinical Associate at the National Cancer Institute from 1970-1971 and Clinical Associate at the Laboratory of Biochemistry of the National Cancer Institute of the National Institute of Health. From 1970 to 1988 he served as an Officer and Medical Director of the United States Public Health Service. Dr. Lippman completed his residency on the Osler Medical Service, John Hopkins Hospital, in Baltimore, Maryland from 1968-1970.

A native of New York, Dr. Lippman received his Bachelor's Degree from Cornell University, Magna Cum Laude, and medical school degree at Yale Medical School in New Haven, CT where he was elected to AOA.

Dr. Lippman is widely known for his research in breast cancer. Throughout his illustrious career he has received numerous awards including Mallinckrodt Award of the Clinical Radioassay Society in 1978; the Commendation Medal USPHS in 1982; Meritorius Service Medal, USPHS in 1987; Clinical Investigator Award, American Federation for Clinical Research in 1985; D.R. Edwards Lecture and Medal, Tenovus Institute, Wales 1985; Plenary Lecturer, British Association of Cancer Research in 1987; Gosse Lecture, Dalhuosie University, Halifax Nova Scotia in 1987; the American Cancer Society.

E-mail a Friend